Key result
In a decision model for 65-year-old patients with average risks, warfarin yielded 12.1 QALYs compared to 10.8 for aspirin and 10.1 for no therapy, though benefits narrowed with higher bleeding risk.
Why the study?
Does the choice of antithrombotic therapy improve quality-adjusted life-years in older patients with atrial fibrillation based on their risk of upper GI bleeding?
Does the choice of antithrombotic therapy improve quality-adjusted life-years in older patients with atrial fibrillation based on their risk of upper GI bleeding?
Absolute Event Rate: 12.1% vs 10.1%
In older patients with atrial fibrillation, the optimal antithrombotic therapy to prevent stroke varies based on the individual's competing risks of stroke and upper gastrointestinal bleeding.
No takes yet. Share an insight, caveat, or question.
Bleeding risk should guide antithrombotic selection in older AF patients; leaves open prospective validation of model-derived thresholds.
Man‐Son‐Hing et al. (2002) studied Atrial fibrillation. Warfarin vs. Aspirin or no antithrombotic therapy was evaluated on Quality-adjusted life-years (QALYs). In a decision model for 65-year-old patients with average risks, warfarin yielded 12.1 QALYs compared to 10.8 for aspirin and 10.1 for no therapy, though benefits narrowed with higher bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: